期刊
CNS DRUGS
卷 25, 期 1, 页码 17-36出版社
ADIS INT LTD
DOI: 10.2165/11538450-000000000-00000
关键词
-
资金
- Janssen-Cilag
- Department of Health of the Government of Catalonia (Generalitat de Catalonia, Spain)
- Fundacion Alicia Koplowitz
- Laboratorios Rubio
- Shire
- Eli Lilly
Remission should be the goal of attention-deficit hyperactivity disorder (ADHD) treatment. However, there is no universally accepted definition of remission in ADHD, although clinical studies use a number of criteria. This article examines current research into the concept of remission in ADHD by reviewing the literature for definition and achievement of remission in children and adults with ADHD. Results demonstrate that the concept of remission in ADHD has been proposed by several study groups, using thresholds of validated rating scales to indicate syndromic, symptomatic and functional remission. Several studies have demonstrated the achievement of remission in ADHD children utilizing methylphenidate delivered by an osmotic, controlled-release formulation (OROS (R)) and atomoxetine. However, none has defined a time period over which these criteria must be met for an individual with ADHD to be considered 'in remission'. Standardized remission criteria in ADHD will provide a tool for assessing the effectiveness of treatments for ADHD, and raise treatment standards.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据